Following a special meeting of its stockholders, Seagen Inc. (Nasdaq: SGEN) today announced that its stockholders voted to approve a proposal to adopt the ...
A type of artificial intelligence (AI), Deep Learning (DL) technology can advance medical imaging capabilities by providing more robust, accurate, and da...
The grant will fund additional patient dosing studies to identify predictive biomarkers of activity and target engagement of TRE-515 in solid tumors. Treth...
HMBD-002, a non-depleting, high-affinity anti-VISTA antibody, possesses key design features enabling robust anti-tumor activity in pr...
INPEFA reduced the risk of total occurrence of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits by 33% compared to ...
First Potential Approval of an Individualized, One-Time Cell Therapy for Patients with Advanced Melanoma Iovance Biotherapeutics, Inc. (NASDAQ: IOVA...
Utilizing cutting-edge high-throughput sequencers, sequencing strategies, and advanced bioinformatics pipelines, the service is ideal for academic, clinica...
— Prescription Drug User Fee Act (PDUFA) Target Action Date set for November 30, 2023 — — NDA includes results from the Phase III FRESCO...
Veeva Systems (NYSE: VEEV) announced that leaders from Bayer, Boehringer Ingelheim, GSK, LEO Pharma, Recordati, and Syneos Health are among the speak...
As a member of the APN, Healthy Together will have access to a wide range of tools and resources to help them optimize their cloud solutions and improve th...
"Already a leader in the industry, Laker Software is going from good to great,” said Jeff Mallad, VP, PBM Technology Sales for Elixir. "Elixir’...
New clinical development of a novel breast cancer diagnostic panel to “upstage” patients at time of diagnoses -BPGbio, Inc.,...
Research from Eascra Biotech will be onboard Axiom Mission 2 (Ax-2), a private crew mission to the International Space Station set to launch Sunday May 21 ...
8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (...
© 2024 Biopharma Boardroom. All Rights Reserved.
